￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
028-123456789
Menu

Medical News

Can Lorlatinib be used as first-line therapy for ALK+ NSCLC?

2025-10-19 11:44:20

Check Details
Effect data of patients with ALK/ROS1 rearranged NSCLC treated with Lorlatinib

2025-10-19 11:44:20

Check Details
The new generation ALK/ROS1 inhibitor Lorlatinib was granted breakthrough drug designation by the FDA

2025-10-19 11:44:20

Check Details
How effective is lorlatinib in the first-line treatment of metastatic non-small cell lung cancer?

2025-10-19 11:44:20

Check Details
Dosage and treatment regimen of Dacomitinib/Dozerun in the treatment of advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
New lung cancer drug dacomitinib has significant effect in treating Chinese patients

2025-10-19 11:44:20

Check Details
Efficacy and safety of dacomitinib in first-line treatment of metastatic non-small cell lung cancer

2025-10-19 11:44:20

Check Details
The efficacy of dacomitinib in the first-line treatment of advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
Dacomitinib, a new targeted drug for lung cancer, can significantly extend the survival time of advanced lung cancer_ Kanghule

2025-10-19 11:44:20

Check Details
The advent of dacomitinib has changed the treatment landscape of EGFR-positive lung cancer!

2025-10-19 11:44:20

Check Details
Contraindications and precautions for patients with lung cancer taking dacomitinib

2025-10-19 11:44:20

Check Details
None

2025-10-19 11:44:20

Check Details
Category
相关知识